c-Myc has been found to be amplified in more than half of refractory prostate cancers (Bernard et al, 2003; Clegg et al, 2011) and has been identified as one of the key players in cell potency (Takahashi et al, 2007), but the factors which mediate its downstream effects in late-stage prostate cancer are still not well understood. This evidence concerns the gene MYC and prostate carcinoma.